South Asia's first state-of-the-art facility to manufacture In Vitro Diagnostics reagent in India for the emerging markets of the world
- Mr. Swaran Singh, IAS to inaugurate the facility at Chennai
- Indigenous manufacturing of high quality IVD Reagents at the Trivitron Medical Technology Park to enhance access to cost effective diagnosis
“With healthcare costs becoming prohibitive, it is imperative that initiatives like this one be promoted aggressively,” he added.
Trivitron Medical Technology Park is South Asia’s first of its kind manufacturing facility situated at Irungattukottai near Chennai. Becoming the hub of Tamil Nadu’s initiative for promoting the state as a manufacturing hub, Chennai is also recognised worldwide for its renowned clinical expertise and as a medical destination.
Trivitron has collaborated with Biosystems, Spain, one of the leading manufacturers of clinical chemistry reagents & instruments, immunofluorescence reagents & instruments, immunoturbidimetry reagents, etc for over 3 decades for a joint venture to establish this manufacturing facility. This is a step towards Trivitron’s multi modality medical technology leadership with innovation and manufacturing facilities in medical technology space. This initiative to set up manufacturing unit in Irugatukottai will boost the image of India on global map and showcase indigenous manufacturing capabilities worldwide.
Dr. G.S.K Velu, commenting on the occasion, said “This plant would be incorporating all contemporary technologies and comply with European Standards for its operations and would be at par with the global standards in every way. The plant design is scalable to double the capacity in future. This facility will produce reagent worth over 200 crore during next 3 to 5 years and it would not only cater to the domestic market but also supply to the other overseas markets.”
“Our association with Trivitron will successfully help the two leading companies to leverage its respective strengths in marketing and manufacturing. The BioSystems Diagnostics Pvt. Ltd (BDPL) manufacturing plant is a one of its kind manufacturing facility designed following international standards including ISO, GMP-DCA to manufacture and market Clinical Diagnostic products.” said Mr. Antonio Elduque, CEO, Biosystems, Spain.
Established in the year 1997, Trivitron is the largest Indian MNC in Medical Technology. It is the only Multi Modality Medical Technology Company in India with presence in Cardiology and Implantable Devices (CID), Imaging Sciences, Lab Diagnostics (IVD) , Critical Care & Life Support Solutions (CLSS) and Ophthalmology. Headquartered in Chennai, Trivitron group's products are now exported to over 160 countries including advanced markets like USA, Europe and Japan. Trivitron has three internationally accredited and world-class Manufacturing facilities in Chennai/ Mumbai and Pune , producing a range of Imaging diagnostics products including Ultrasound and Color Doppler machines, X Ray equipments, image enhancement solutions and radiation protection apparels, Cardiac Diagnostics Instruments, an entire range of Operating Room solutions, and In Vitro Diagnostics (IVD) instruments and reagents.
For further information log on to www.trivitron.com
Biosystems was first founded in 1981; it offers effective, reliable analytical systems to laboratories around the world. Their mastery in core technologies combined with extensive experience offer ground-breaking products that are tailored to customers’ needs and enhanced through an ongoing improvement process.
Biosystems offers an extensive, far-reaching range of clinical diagnostics products to boost work flow efficiency, maximize operational effectiveness and improve patient treatment. To contribute to improvements in personal health worldwide, provide clinical analyses laboratories with highly reliable, state-of-the-art instruments and reagents.
For further information logon to http://www.biosystems.es/
Make a pledge to a healthier life on World Cancer Day - Together it is possible
Chennai, February 4th, 2012 - Trivitron Healthcare, the largest medical technology company of Indian origin,observes the World Cancer Day on 4th February asking everyone in to make a pledge to join in the global fight against cancer - it is only by every person, organisation, and government individually doing their part that the world will be able to reduce premature deaths from this devastating disease.
Dr.G.S.K.Velu, Managing Director, Trivitron Group of Companies echoed the belief that we can reduce deaths from non- communicable disease such as cancer. This is only possible if together we take responsibility to achieve impactful interventions. He also added, ““Breast cancer &Cervical cancer are the top two commonest malignancies afflicting women. According to recent research data, over 16 percent of Indian women in the age group of 40-60 years face a potential risk of breast cancer. Beyond this, delayed detection can result in 1 of every 22 women actually developing breast cancer. As the pioneering medical technology leader, Trivitron is committed to fight the menace of cancer.One in three cancer deaths can be prevented through changing lifestyle habits, such as eating healthily, exercising regularly, not smoking and reducing alcohol consumption. Therefore, a key mission of World Cancer Day 2012 is to collect pledges and encourage people across the world to commit to positive lifestyle change to reduce their cancer risk.
Paul Stephen, Head, Imaging Diagnostics, Trivitron added, “Cancer knows no boundaries, so we all must take responsibility for beating this devastating disease. Together it is possible.”
Taking place every year on 4 February, World Cancer Day is the singular initiative under which the entire world can unite together in the fight against the global cancer epidemic. Urgent action against cancer is vital because the human suffering and economic impact of the disease is huge and only set to rise.
NitinSawant, Head, Diagnostics, Trivitron added, “As a part of our commitment to bring world class medical technology at affordable cost in India and other emerging markets, we are proud to be the first in South Asia to bring advanced technologies including 3-D digital mammography system (Tomosynthesis), Liquid Based Cytology solutions for an early detection and improved chances of survival.
Our technologies help doctors see better; know sooner; reach further and touch more lives.
About Trivitron Healthcare (www.trivitron.com):
Putting India on Global Map of Medical Technology
For more than a decade, we have been bringing quality medical technology to healthcare providers across India and emerging markets of the world. Established in 1997, today we can proudly say, almost every healthcare institution in India uses Trivitron Technology. Being at the forefront of medical technology in India and driving our dream of indigenous medical technology to fruition, we today design, innovate, build and manufacture medical technology across the entire spectrum of healthcare requirements. Associating with key global leaders in medical technology and having the best reach across the country, we bring you technology that truly delivers.
Trivitron was floated with the concept of Ear to the ground approach, understanding and speaking customer's own language. With group revenues in excess of Rs.400 crores in FYI 12 and anticipated revenue of Rs.500 crores, Trivitron today is the largest Medical Technology Company of Indian Origin, with an ambition to grow to over Rs.1000 crs by 2013, with more than two thirds of revenues coming from Manufacturing, Services and International Operations. Trivitron's vision is to think Out of Box to make the most innovative Medical Technology products affordable to the larger section of population in the Emerging Markets with particular focus to India, South Asia, Middle East and Africa.
Being an Emerging Market brand, Trivitron understand medical technology should meet needs and not only purposes. Our aim is to enhance access and affordability of healthcare by all by combining local innovation, Frugal Engineering, Partnership with MNCs and local acquisition strategies.
Trivitron’s key focus areas are Imaging Sciences, Laboratory Medicine and Cardiology (equipment and devices) and will be looking forward to futuristic areas including Ophthalmology, Dental and Critical Care & OR, boasting of Industry's one of the most comprehensive product offerings in both Value and Premium segments. Trivitron operates ensures coverage through its 18 offices, 10 warehouses, own Sales and Service infrastructure of over 500 professionals and a Dealer base of over 700 dealers located in different locations focused on different products. Every major hospital in India uses atleast one of Trivitron's products either manufactured by us or distributed exclusively by us in India in our own brand or our partner's brand. Trivitron’s customer care is accessible 24/7 throughout the year on the helpline, +91-98400 80008
With our stated goal of bringing high quality, cost effective medical technology solutions to emerging markets around the world, we are currently present in Sri Lanka, the Middle East, South Africa and are expanding our presence in South Asia, South East Asia and Africa.
In the near future, we aim to grow into a Rs.1000 crore company reaching further into international markets with high cost effective medical technology solutions and truly putting India on the global map of Medical Technology. Trivitron continues to grow and expand in its quest to provide the healthcare industry with the best and most cost effective technology and solutions available.
Trivitron has been awarded with Frost & Sullivan Growth, Innovation and Leadership award for the year 2010(the only healthcare company to receive the award) for spearheading the manufacturing and innovation in medical technology space. With this award, Trivitron Healthcare’s leadership in defining a new era in the medical technology has been recognized internationally.